- Home
- MNKD vs BHVN Comparison
MNKD vs BHVN Comparison
Compare MNKD & BHVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNKD
- BHVN
- Stock Information
- Founded
- MNKD 1991
- BHVN 2013
- Country
- MNKD United States
- BHVN United States
- Employees
- MNKD N/A
- BHVN N/A
- Industry
- MNKD Biotechnology: Pharmaceutical Preparations
- BHVN Biotechnology: Pharmaceutical Preparations
- Sector
- MNKD Health Care
- BHVN Health Care
- Exchange
- MNKD Nasdaq
- BHVN Nasdaq
- Market Cap
- MNKD 1.6B
- BHVN 1.9B
- IPO Year
- MNKD 2004
- BHVN 2017
- Fundamental
- Price
- MNKD $4.54
- BHVN $20.37
- Analyst Decision
- MNKD Buy
- BHVN Strong Buy
- Analyst Count
- MNKD 6
- BHVN 14
- Target Price
- MNKD $8.92
- BHVN $63.15
- AVG Volume (30 Days)
- MNKD 2.2M
- BHVN 1.7M
- Earning Date
- MNKD 05-07-2025
- BHVN 05-08-2025
- Dividend Yield
- MNKD N/A
- BHVN N/A
- EPS Growth
- MNKD N/A
- BHVN N/A
- EPS
- MNKD 0.10
- BHVN N/A
- Revenue
- MNKD $285,504,000.00
- BHVN N/A
- Revenue This Year
- MNKD $14.23
- BHVN N/A
- Revenue Next Year
- MNKD $14.56
- BHVN $65.26
- P/E Ratio
- MNKD $45.40
- BHVN N/A
- Revenue Growth
- MNKD 43.50
- BHVN N/A
- 52 Week Low
- MNKD $3.97
- BHVN $15.79
- 52 Week High
- MNKD $7.63
- BHVN $55.70
- Technical
- Relative Strength Index (RSI)
- MNKD 28.12
- BHVN 39.78
- Support Level
- MNKD $4.34
- BHVN $15.79
- Resistance Level
- MNKD $4.72
- BHVN $19.30
- Average True Range (ATR)
- MNKD 0.21
- BHVN 2.20
- MACD
- MNKD -0.01
- BHVN 0.26
- Stochastic Oscillator
- MNKD 27.03
- BHVN 42.84
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.
About BHVN Biohaven Ltd.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.